Stereochemistry | ACHIRAL |
Molecular Formula | C11H12N3O.CH3O4S |
Molecular Weight | 313.33 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
COS([O-])(=O)=O.COC1=CC(N)=CN=[N+]1C2=CC=CC=C2
InChI
InChIKey=ZEASXVYVFFXULL-UHFFFAOYSA-N
InChI=1S/C11H11N3O.CH4O4S/c1-15-11-7-9(12)8-13-14(11)10-5-3-2-4-6-10;1-5-6(2,3)4/h2-8,12H,1H3;1H3,(H,2,3,4)
Molecular Formula | C11H11N3O |
Molecular Weight | 201.2245 |
Charge | 0 |
Count |
MOL RATIO
1 MOL RATIO (average) |
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | CH4O4S |
Molecular Weight | 112.105 |
Charge | 0 |
Count |
MOL RATIO
1 MOL RATIO (average) |
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Amezinium is a sympathomimetic used for its vasopressor effects in the treatment of hypotensive states. Amezinium inhibited monoamine oxidase (MAO) activity. Amezinium antagonized the response to tyramine and blocked neuronal uptake of noradrenaline. Side effects revealed are: palpitation, headache, nausea/vomiting, hot flashes, high blood pressure.
Originator
Approval Year
PubMed
Patents
Sample Use Guides
Amezinium antagonized the response to tyramine and blocked neuronal uptake of noradrenaline m concentrations as low as 0.1 to 10 uM and therefore it was not surprising to find that in the presence of the lower concentration of
Amezinium the effects of noradrenaline were potentiated (at the level of the ED50) by a factor of 3.5.